Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

British Journal of Haematology

Volumn 113, Issue 4, 2001, Pages 1035-1043

  McCloskey, Eugene V ^a   Dunn, Janet A ^b   Kanis, John A ^a   MacLennan, Ian C M ^c   Drayson, Mark T ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Clodronate; Myelomatosis; Prognosis; Survival; Vertebral fractures

Indexed keywords

CARMUSTINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; MELPHALAN; PREDNISOLONE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; ANALGESICS, NON-NARCOTIC; CHI-SQUARE DISTRIBUTION; CLODRONIC ACID; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SPINAL FRACTURES; SURVIVAL ANALYSIS;

EID: 0034937438     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02851.x     Document Type: Article

References (26)

1. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
2. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
3. Regression models and life-tables
4. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
5. Treatment of Early Breast Cancer
6. Longterm controlled trial with diphosphonate in patients with osteolytic bone metastases
7. Treatment of skeletal disease in breast cancer: A controlled clodronate trial
8. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro
9. Regulation of osteoclast activity
10. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group
11. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group
12. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
13. Non-parametric estimation from incomplete observations
14. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages
15. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis
16. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
17. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials
18. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
19. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II Analysis and example
20. Prospective, controlled, non randomized study on prophylactic parenteral dichloremethylene bisphosphonate (clodronate) in multiple myeloma
21. Molecular mechanisms of action of bisphosphonates
22. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
23. Treatment of multiple myeloma
24. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity
25. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway
26. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group